Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von StockNews.com 

Cellectar BioSciences Inc. diskutieren

Cellectar BioSciences Inc.

WKN: A3DQSD / Symbol: CLRB / Name: Cellectar BioSciences / Aktie / Pharmazeutika / Micro Cap /

2,84 €
3,55 %

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CLRB provided by MarketBeat

Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for CLRB provided by MarketBeat

Einschätzung Buy
Rendite (%) -22,83 %
Kursziel 18,41
Veränderung
Endet am 04.03.25

Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $20.00 price target on the stock.
Ratings data for CLRB provided by MarketBeat

Einschätzung Buy
Rendite (%) -23,66 %
Kursziel 11,09
Veränderung
Endet am 28.03.25

Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock, up previously from $11.00.
Ratings data for CLRB provided by MarketBeat

Einschätzung Buy
Rendite (%) -23,66 %
Kursziel 25,93
Veränderung
Endet am 28.03.25

Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target raised by analysts at Roth Mkm from $20.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for CLRB provided by MarketBeat

Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for CLRB provided by MarketBeat